✦ LIBER ✦

Coagulation disorders in cancer. III. Fibrinolysis and inhibitors

✍ Scribed by Bernadette C. F. Soong; Sherwood P. Miller

Publisher: John Wiley and Sons
Year: 1970
Tongue: English
Weight: 738 KB
Volume: 25
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197004)25:4<867::aid-cncr2820250417>3.0.co;2-c

No coin nor oath required. For personal study only.

✦ Synopsis

I n a group of 100 unselected patients with disseminated malignancies, marked disturbances i n the coagulation and fibrinolytic systems were found. Mean silicone coagulation time was shortened, and fibrinogen levels were markedly elevated. Fibrinolysis activation, as manifested by plasma clot lysis, euglobulin lysis, or the presence of fibrin degradation products, was noted in 9 cases. Mean plasmhogen levels were normal. There was a significant elevation of urokinase inhibitor, but other inhibitors of fibrinolysis were normal.

HE ASSOCIATION BETWEEN MALIGNANT DIS-

T ease and thrombosis has long been recognized.35 In recent years, attention has also been drawn to the occurrence of hemorrhagic disorders in cancer.10. 31 There have been numerous attempts to elucidate the mechanism of this disturbance in hemostatic function.9~ 11. 17, 27. 28 Previous studies from this laboratory have demonstrated a profound disturbance in the coagulation system in cancer.19. 2O The outstanding features included a marked tendency to elevation of coagulation factor levels (especially Factors I, V, VIII, IX, and XI), with an associated shortening of the silicone coagulation time and recalcification time, and acceleration of thromboplastin generation.

It was also demonstrated that the fibrinolytic process had been activated in 6 of 50 patients. This was manifested by one or more of the following positive tests: whole blood clot lysis, plasma dilution clot lysis, euglobulin clot lysis, and positive immunologic test for fibrin degradation products (FDP). A close correlation in individual patients between elevated clotting factors and the occurrence of clinical abnormalities was not observed. It was, therefore, decided to study

📜 SIMILAR VOLUMES

Coagulation and fibrinolysis disorder in

Coagulation and fibrinolysis disorder in muscular dystrophy

✍ Toshio Saito; Marina Takenaka; Ichiro Miyai; Yuko Yamamoto; Tsuyoshi Matsumura; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

To investigate whether there are any basic abnormalities of coagulation and fibrinolysis in muscular dystrophy, we measured serum levels of the MM isozyme of creatine kinase (CK-MM), fibrin and fibrinogen degradation products (FDP), plasma levels of fibrinogen, antithrombin (AT), and D-dimer in 36 p

Fibrinolysis, inhibitors of blood coagul

Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria

✍ Mohanty, D.; Ghosh, K.; Nandwani, S.K.; Shetty, S.; Phillips, C.; Rizvi, S.; Par 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Different parameters of fibrinolytic systems like t-PA, PAI, D-dimer, and inhibitors of blood coagulation, i.e., protein C (PC), protein S(PS), and antithrombin III (AT-III), have been studied in cases of acute malaria due to Plasmodium falciparum and plasmodium vivax infection, and these patients w

Coagulation-fibrinolysis system and mark

Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer

✍ Esteban C. Gabazza; Osamu Taguchi; Tomoya Yamakami; Motoko Machishi; Hidenori Ib 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 629 KB

Activation of coagulation and fibrinolys

Activation of coagulation and fibrinolysis during reconstructive microsurgery in patients with cancer

✍ Eija Olsson; Nils Svartling; Sirpa Asko-Seljavaara; Riitta Lassila 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract Cancer patients are subjected to increased systemic risk of thrombotic events and may therefore be at higher risk of even local thrombosis compromising the outcome of reconstructive microsurgery. Coagulation and fibrinolysis activities were studied serially during and after reconstructi

Coagulation disorders in cancer II. mult

Coagulation disorders in cancer II. multiple myeloma

✍ Julio Sanchez-Avalos; Bernadette C. F. Soong; Sherwood P. Miller 📂 Article 📅 1969 🏛 John Wiley and Sons 🌐 English ⚖ 969 KB

Some species differences in fibrinolysis

Some species differences in fibrinolysis and blood coagulation

✍ Mason, R. G. ;Read, M. S. 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB 👁 1 views

The plasminogen levels and the reactivities of plasmas in two commonly used blood coagulation tests have been compared for man and seven mammals. The plasmas of three nonhuman primates in general reacted as did human plasma in tests for plasminogen activation and in reactivity in the partial thrombo